X4 Pharmaceuticals Inc
XFOR5.335USD
+5.145+2707.89%
Fechamento 04/28, 16:00（ET）Cotações atrasadas em 15 min
912.00MValor de mercado
PerdaP/L TTM
Mais detalhes de X4 Pharmaceuticals Inc Empresa
X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. It has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
Informações da empresa
Código da empresaXFOR
Nome da EmpresaX4 Pharmaceuticals Inc
Data de listagemNov 16, 2017
Fundado em2010
CEODr. Paula Ragan, Ph.D.
Número de funcionários143
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 16
Endereço61 North Beacon Street
CidadeBOSTON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal02134
Telefone18575298300
Sitehttps://www.x4pharma.com/
Código da empresaXFOR
Data de listagemNov 16, 2017
Fundado em2010
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Paula Ragan, Ph.D.
Dr. Paula Ragan, Ph.D.
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
36.25K
-67.42%
Dr. Mary Dibiase, Ph.D.
Dr. Mary Dibiase, Ph.D.
Chief Operating Officer
Chief Operating Officer
35.21K
+159.96%
Dr. Christophe Arbet-engels, Ph.D.
Dr. Christophe Arbet-engels, Ph.D.
Chief Medical Officer
Chief Medical Officer
28.81K
+5.98K%
Mr. Mark Baldry
Mr. Mark Baldry
Chief Commercial Officer
Chief Commercial Officer
4.31K
-82.28%
Mr. Michael S. Wyzga
Mr. Michael S. Wyzga
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
2.56K
-36.98%
Dr. Gary J. Bridger, Ph.D.
Dr. Gary J. Bridger, Ph.D.
Director
Director
1.72K
-46.55%
Mr. David W.J. Mcgirr
Mr. David W.J. Mcgirr
Independent Director
Independent Director
--
--
Dr. Murray W. Stewart, M.D.
Dr. Murray W. Stewart, M.D.
Director
Director
--
--
Ms. Francoise De Craecker
Ms. Francoise De Craecker
Independent Director
Independent Director
--
--
Mr. Daniel Ferry
Mr. Daniel Ferry
Managing Director
Managing Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Paula Ragan, Ph.D.
Dr. Paula Ragan, Ph.D.
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
36.25K
-67.42%
Dr. Mary Dibiase, Ph.D.
Dr. Mary Dibiase, Ph.D.
Chief Operating Officer
Chief Operating Officer
35.21K
+159.96%
Dr. Christophe Arbet-engels, Ph.D.
Dr. Christophe Arbet-engels, Ph.D.
Chief Medical Officer
Chief Medical Officer
28.81K
+5.98K%
Mr. Mark Baldry
Mr. Mark Baldry
Chief Commercial Officer
Chief Commercial Officer
4.31K
-82.28%
Mr. Michael S. Wyzga
Mr. Michael S. Wyzga
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
2.56K
-36.98%
Dr. Gary J. Bridger, Ph.D.
Dr. Gary J. Bridger, Ph.D.
Director
Director
1.72K
-46.55%
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Acionista
Tempo de atualização: dom, 23 de fev
Tempo de atualização: dom, 23 de fev
Estatísticas dos acionistas
Tipo
Estatísticas dos acionistas
Acionista
Proporção
Bain Capital Life Sciences Investors, LLC
9.74%
New Enterprise Associates (NEA)
8.63%
BlackRock Institutional Trust Company, N.A.
5.91%
The Vanguard Group, Inc.
4.72%
Acorn Capital Advisors, LLC
4.21%
Other
66.79%
Estatísticas dos acionistas
Acionista
Proporção
Bain Capital Life Sciences Investors, LLC
9.74%
New Enterprise Associates (NEA)
8.63%
BlackRock Institutional Trust Company, N.A.
5.91%
The Vanguard Group, Inc.
4.72%
Acorn Capital Advisors, LLC
4.21%
Other
66.79%
Tipo
Acionista
Proporção
Investment Advisor
25.05%
Investment Advisor/Hedge Fund
11.85%
Venture Capital
8.63%
Hedge Fund
5.73%
Private Equity
4.92%
Individual Investor
2.32%
Research Firm
1.96%
Bank and Trust
0.09%
Pension Fund
0.04%
Other
39.41%
Participação acionária institucional
Tempo de atualização: qua, 5 de mar
Tempo de atualização: qua, 5 de mar
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q1
216
105.29M
60.63%
-54.29M
2024Q4
216
103.66M
60.78%
-53.08M
2024Q3
212
110.90M
65.83%
-43.36M
2024Q2
209
114.19M
68.28%
-40.11M
2024Q1
203
115.38M
69.15%
-30.64M
2023Q4
192
109.42M
65.98%
-32.86M
2023Q3
189
132.64M
89.63%
+450.20K
2023Q2
191
133.25M
115.52%
+52.30M
2023Q1
171
81.27M
73.10%
+5.35M
2022Q4
172
79.41M
72.57%
+27.33M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Bain Capital Life Sciences Investors, LLC
16.92M
9.74%
--
--
Dec 31, 2024
New Enterprise Associates (NEA)
14.99M
8.63%
--
--
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
10.26M
5.91%
-93.42K
-0.90%
Dec 31, 2024
The Vanguard Group, Inc.
8.20M
4.72%
-239.83K
-2.84%
Dec 31, 2024
Acorn Capital Advisors, LLC
7.31M
4.21%
--
--
Dec 31, 2024
OrbiMed Advisors, LLC
7.13M
4.11%
--
--
Dec 31, 2024
Kingdon Capital Management, L.L.C.
4.94M
2.84%
+298.32K
+6.43%
Dec 31, 2024
Geode Capital Management, L.L.C.
3.50M
2.01%
+49.70K
+1.44%
Dec 31, 2024
AXA Investment Managers UK Ltd.
3.07M
1.77%
-4.80K
-0.16%
Dec 31, 2024
State Street Global Advisors (US)
3.06M
1.76%
+104.40K
+3.54%
Dec 31, 2024
Ver Mais
ETFs Relacionados
Tempo de atualização: dom, 6 de abr
Tempo de atualização: dom, 6 de abr
Nome
Proporção
iShares Micro-Cap ETF
0.01%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Value ETF
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
Simplify Propel Opportunities ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Ver Mais
iShares Micro-Cap ETF
Proporção0.01%
ProShares UltraPro Russell2000
Proporção0%
iShares Russell 2000 Value ETF
Proporção0%
ProShares Hedge Replication ETF
Proporção0%
Proshares Ultra Russell 2000
Proporção0%
Simplify Propel Opportunities ETF
Proporção0%
iShares Core S&P Total U.S. Stock Market ETF
Proporção0%
Global X Russell 2000 ETF
Proporção0%
iShares Russell 2000 ETF
Proporção0%
Invesco NASDAQ Future Gen 200 ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados